Background/Aims: Temple syndrome is an imprinting disorder caused by maternal uniparental disomy of chromosome 14 (mat UPD14), paternal deletion of 14q32 or paternal hypomethylation of the intergenic differentially methylated region (MEG3/DLK1 IG-DMR). Patients with Temple syndrome have pre-and postnatal growth restriction, short stature, hypotonia, small hands and feet and precocious puberty. We sought to determine whether treatment with growth hormone improves growth outcomes in patients with Temple syndrome. Methods: This was a retrospective observational study reviewing the medical records of 14 patients with Temple syndrome, 7 of whom were treated with growth hormone. Results: After 1 year of growth hormone treatment, the height standard deviation score (SDS) increased a median of 1.31 SDS with a median increased height velocity of 5.30 cm/year. Conclusions: These results suggest short-term improvement in height SDS with growth hormone treatment similar to the response in patients treated under the small for gestational age indication. We recommend considering growth hormone therapy in all patients with Temple syndrome who have short stature.
Introduction
Temple syndrome is an imprinting disorder of chromosome 14 that was first described in 1991 [1] . In a comprehensive review of 51 published cases, Ioannides et al. [2] showed that patients with Temple syndrome have reduced pre-and postnatal growth, hypotonia, facial dysmorphia, small feet and hands, and short stature in addition to precocious puberty. Additionally, half of patients with Temple syndrome are obese. Temple syndrome can result from maternal uniparental disomy (UPD) of chromosome 14 (70-80% of cases), paternal deletion of a region including DLK1 and GTL2/MEG3 (10% of cases), paternal hypomethylation of the intergenic differentially methylated region (MEG3/DLK1 IG-DMR) (12% of cases) and paternal deletion of the IG-DMR (less than 2% of cases) [2] [3] [4] [5] [6] . A smaller paternal deletion in 14q32 only affecting the DLK1 gene DOI: 10.1159/000496700 causes precocious puberty, one of the features of Temple syndrome [7] . Despite the significant growth attenuation, no Temple syndrome-specific growth curves are available, and little is known about growth response during and after growth hormone treatment in these patients [4] .
The incidence of Temple syndrome is unknown, and it is likely underdiagnosed because of variability in the phenotype and overlap of symptoms with other disorders such as Prader-Willi syndrome (PWS) and SilverRussell syndrome (SRS) [2, [8] [9] [10] . The non-specific symptoms of Temple syndrome make clinical diagnosis difficult. A subset of children with Temple syndrome will meet criteria for the clinical diagnosis of SRS [10] [11] [12] [13] . Although Temple syndrome and PWS share some clinical features, the tempo of puberty differs between the syndromes. Gonadotropin-dependent precocious puberty is a feature of Temple syndrome whereas premature pubarche and delayed or incomplete puberty is observed in PWS [4] .
Precocious puberty, which promotes an early pubertal growth spurt and skeletal maturation, causes bone age acceleration and contributes to short stature in patients with Temple syndrome [4, 14, 15] . As a result, some of these patients are treated with long-acting gonadotropin-releasing hormone (GnRH) analogue to delay puberty [4, 8, 13, 16] . In order to increase stature, growth hormone treatment must occur before puberty triggers bone age acceleration and epiphyseal closure [17] .
In clinical practice, some patients with Temple syndrome are treated with growth hormone to increase growth and stature under the currently approved clinical indication of being short secondary to being born small for gestational age. The overlap with SRS is also used as a rationale for growth hormone treatment following the SRS consensus [18] . However, to date, there are only 12 individuals reported in the literature who have been treated with growth hormone [8, 12, 19, 20] . Of these, growth curves were published for 10 individuals, but a quantitative assessment of growth hormone response has not been performed in a cohort of these patients. Therefore, there is inadequate evidence to determine whether or not growth hormone treatment improves height outcomes for patients with Temple syndrome [12, 19, 20] . Here, we report a quantitative review of an additional 6 patients with Temple syndrome who were treated with growth hormone and their outcomes to determine whether growth hormone should be recommended as the standard course of treatment.
Methods

Study Design and Population
This study was approved by the Institutional Review Board of Cincinnati Children's Hospital Medical Center (CCHMC) in Cincinnati, OH, USA. This is a retrospective observational study in which we recruited patients with a molecular diagnosis of Temple syndrome including maternal UPD14 (mat UPD14), paternal deletion of 14q32 and paternal hypomethylation of the MEG3/DLK1 IG-DMR. Recruitment occurred from a number of different sources. First, we recruited a patient with a molecular diagnosis of Temple syndrome from the Genetics and Endocrinology clinics at CCHMC. Other participants were recruited from the Wessex Imprinting Group at the University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK, at which medical and research records for eligible patients were reviewed after patients were contacted for their consent. Some of the cases were also part of the STAARS cohort (the Study of Adults and Adolescents with Russell-Silver syndrome). Additionally, a study announcement was sent to a Temple syndrome parents' support group on Facebook and interested patients were invited to contact the study staff. Similarly, eligible patients from the Unique -Rare Chromosome Disorder Support Group were sent information about the study and invited to contact study staff. To be included, patients or their parent, if under the age of 18, had to be able to participate in a telephone or Skype interview. Participants were excluded if they had other additional genetic diagnoses or a paternal deletion of 14q32 over 5 MB in size because larger deletions could contain other essential genes that alter the phenotype.
Procedures
Informed consent was obtained via telephone or Skype and the patient or their parent (if the patient was under the age of 18) signed a written consent form. Telephone or Skype interviews were performed with the patient's parent to obtain patient demographics, parental heights, pubertal data, height, weight and head circumference at birth, diagnoses of hypotonia, feeding difficulties, history of diabetes and developmental delays as well as history of treatment with growth hormone or medications to delay puberty. Medical records were acquired and growth measurements (height and weight), growth hormone treatment information, timing of puberty and genetic aetiology of Temple syndrome were documented. Standardized case report forms were used for both the interview and data abstraction from the medical record. The most important outcome variable was age-specific height measurements from which height velocity and height standard deviation score (SDS) were calculated using US CDC norms. For patients who received growth hormone, the height velocity (cm/year) for the year prior to growth hormone treatment and the height velocity over the first year of treatment was calculated. For the UK participants, written consent forms were available or completed before the study. Medical records were reviewed for all data collection.
Results
Participant Demographics
We enrolled 14 patients with Temple syndrome (3 male and 11 female) in this study ( median age of 4.8 years (IQR: 3.9-11.2 years). Participants were from the USA, UK, Norway and Australia, all of whom reported Caucasian ancestry with the exception of 1 participant who reported half-Caucasian, half-Brazilian ancestry. Genetic aetiologies include mat UPD14 for 13/14 participants, 1 of whom had additional mosaicism for Trisomy 14, and 1 participant who had an epimutation (paternal hypomethylation of the MEG/DLK1 IG-DMR region). The median age at diagnosis was 2 years (IQR: 0.50-9.4 years).
Clinical Phenotype
All participants (14/14) reported hypotonia and most participants (13/14) were reported to have feeding difficulties in early life. All participants were reported to have at least one developmental delay with 93% reporting motor delay (13/14) and 93% reporting speech delay (13/14) . One participant (1/3) had cryptorchidism. Two participants definitely met clinical criteria for SRS, scoring 4 out of 6 on the Netchine-Harbison clinical scoring system (online suppl. Table 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000496700) [18] . One of these participants previously had negative genetic testing for SRS (for H19 hypomethylation and UPD7). Due to the limitations of a retrospective chart review, we were unable to assess all of the necessary clinical parameters of the Netchine-Harbison scoring system in the majority of subjects, and thus, we cannot provide an accurate estimate of the percentage of patients who met clinical criteria of SRS.
At the time of interview, 5/14 participants (1 male and 4 females) had undergone puberty with the male (participant 8) reporting pubarche between 9 and 10 years of age and the females (participants 4, 11, 12 and 14) reporting thelarche at a median age of 6.8 years (range 4.3-9 years). Two subjects underwent treatment with a GnRH analogue to suppress pubertal development.
Growth
Participants were born at a median of 38 weeks (IQR: 37.0-39.2 weeks) of gestation ( Table 2) . Three participants were delivered prematurely at 30, 36 and 36.7 weeks, respectively. Participants had a median birth weight of 2,074 g (IQR: 1,984-2,361 g) and a median birth length of 47 cm (IQR: 45.7-48.3 cm), and 86% (12/14) were small for gestational age (birth weight or length below -2 SDS). Of these, 7 were treated with growth hormone. The most recent height SDS or height SDS prior to the start of growth hormone treatment for all participants was a median of -2.60 SDS (IQR: -3.03 to -2.49 SDS).
Participants 1-7 were treated with growth hormone (Table 3) . No medical records could be obtained for participant 7. Of the 6 participants for whom we have growth data, the median age at initiation of growth hormone treatment was 3.3 years (range: 2.3-4.1 years) at which the median height SDS was -2.52 SDS (range: -3.32 to -2.28 
Discussion
Growth hormone treatment is approved for a variety of indications other than growth hormone deficiency including small for gestational age [21] . As we learn more about the genetic aetiologies of patients who are small for gestational age, patients are being re-characterized by their genetic diagnoses. Many patients with Temple syndrome are also born small for gestational age and some are currently being treated with growth hormone under the small for gestational age indication. Some patients with Temple syndrome also have phenotypic overlap with SRS, another imprinting disorder that includes phenotypes of small for gestational age, postnatal growth failure and feeding difficulties [10] [11] [12] [13] . In our study, 2 participants met clinical criteria for SRS using the NetchineHarbison clinical scoring system with most of the remainder having inadequate data to fully assess. Patients with SRS are treated with growth hormone under the small for gestational age indication, and studies have shown that these patients have increased growth in response to therapy [22] . Whether patients with Temple syndrome, including those who meet clinical criteria for SRS, have improved outcomes with growth hormone treatment has not yet been proven.
In this study we provide a quantitative assessment of response to growth hormone in patients with Temple syndrome. Previously published reports have described treatment of growth hormone in patients with Temple syndrome, but reports have been descriptive and/or included only a small sample size. One previous report described a single patient who was treated with growth hormone and had improvement of height SDS from -2.5 to -1.5 from the age of 6 to 12 years [8] . The report did not include height velocity data or dosage of growth hormone. A second study prospectively followed the response to growth hormone in 2 patients with Temple syndrome in which both patients had increased height SDS over 1 year of treatment (0.9 and 0.8 height SDS) [19] . Another study published growth curves for 8 patients with Temple syndrome who were treated with growth hormone [12] . The authors described accelerated statural growth in 7 of the 8 patients and no response in 1 of the patients [12] . While this is the largest treated cohort to date, quantitative analysis of the growth response was not included.
Herein, we describe 14 patients with Temple syndrome with a median age of 5 years. Of the patients, 12 were born small for gestational age and 7 were treated with growth hormone. Our study suggests that significant short-term improvement in height SDS occurs when patients with Temple syndrome are treated with growth hormone. In our study, patients who were treated with a median dose of 0.04 mg/kg/day (of growth hormone for 1 year) had a median increased height of 1.31 SDS and increased height velocity of 5.30 cm/year. There are very limited data on long-term response to growth hormone treatment in Temple syndrome. However, these results are similar to the short-term response seen in patients born small for gestational age in which the mean height SDS increased 1.2-2.0 SDS after 3 years of growth hormone treatment at 0.035-0.07 mg/kg/day [23] . Our patients' mean first year height velocity of over 11 cm/year is quite robust. Unfortunately, longitudinal bone age data were not available in our cohort and thus we cannot comment on the effect of growth hormone on predicted adult height.
The patients in our study were quite young and most (9/14) had not yet experienced puberty. Precocious puberty, one of the features of Temple syndrome, can contribute to short stature. It is critical to monitor all of these patients for the development of precocious puberty so that GnRH agonist therapy can be initiated in a timely fashion as early as possible in childhood. Long-term observational studies are required to determine the effects of growth hormone treatment in addition to GnRH agonist treatment on final adult height in the context of precocious puberty in Temple syndrome. In this cohort, all but one patient had Temple syndrome caused by maternal UPD of chromosome 14. We cannot therefore comment on response to growth hormone in Temple syndrome caused by an epimutation or a paternal deletion. Additionally, we were not able to age-match treated with untreated participants due to unavailability of growth data at younger ages for some of the untreated participants. Despite the small number of treated patients in our cohort, the data suggest that patients with Temple syndrome have similar short-term response to growth hormone as patients currently treated under the approved indication of being born small for gestational age. Children with other imprinting disorders (PWS and SRS) are given recombinant growth hormone to optimize body composition and linear growth. It is important to note that all of the patients in our study were diagnosed with hypotonia. It is possible that growth hormone treatment may improve muscle tone in these patients as is seen in PWS, and muscle tone should be monitored for improvement while on treatment. Furthermore, the growth pattern of Temple syndrome mirrors that observed in children born small for gestational age who fail to catch up in growth and that observed in children with SRS. Temple syndrome, another imprinting disorder, has phenotypic features similar to SRS, but effects of growth hormone on body composition or other non-growth-related parameters have not been assessed. Obesity is a particular concern in this patient population and early prevention of obesity is necessary, similar to what has been recom- GH, growth hormone; height SDS, height standard deviation score; Tx, treatment; Δ height SDS, increase in height SDS after 1 year of treatment; pre-Tx, height velocity in the year prior to growth hormone treatment; postTx, height velocity over the first year of treatment; n/a, not available. a Participant 3 only received 9 months of growth hormone treatment.
DOI: 10.1159/000496700 mended in SRS [18] . We recommend that growth hormone is considered in all patients with Temple syndrome who have short stature along with careful monitoring of pubertal development and treatment of precocious puberty. These measures may improve growth in patients with Temple syndrome.
